» Articles » PMID: 25360743

Acceptability and Correlates of Primary and Secondary Prevention of Cervical Cancer Among Medical Students in Southwest China: Implications for Cancer Education

Overview
Journal PLoS One
Date 2014 Nov 1
PMID 25360743
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To understand knowledge about, and acceptability of, cervical cancer screening and HPV vaccines among medical students; and to explore potential factors that influence their acceptability in China.

Methods: We conducted a survey among medical students at six universities across southwest China using a 58-item questionnaire regarding knowledge and perceptions of HPV, cervical cancer, and HPV vaccines.

Results: We surveyed 1878 medical students with a mean age of 20.8 years (standard deviation: 1.3 years). Of these, 48.8% and 80.1% believed cervical cancer can be prevented by HPV vaccines and screening respectively, while 60.2% and 71.2% would like to receive or recommend HPV vaccines and screening. 35.4% thought HPV vaccines ought to be given to adolescents aged 13-18 years. 32% stated that women should start to undergo screening from the age of 25. 49.2% felt that women should receive screening every year. Concern about side effects (38.3% and 39.8%), and inadequate information (42.4% and 35.0%) were the most cited barriers to receiving or recommending HPV vaccination and cervical cancer screening. Females were more likely to accept HPV vaccines (OR, 1.86; 95% CI: 1.47-2.35) or cervical cancer screening (OR, 3.69; 95% CI: 2.88-4.74). Students with a higher level of related knowledge were much more willing to receive or recommend vaccines (P<0.001) or screening (P<0.001). Students who showed negative or uncertain attitudes towards premarital sex were less likely to accept either HPV vaccines (OR, 0.67; 95% CI: 0.47-0.96), or screening (OR, 0.68; 0.47-0.10). Non-clinical students showed lower acceptability of cervical screening compared to students in clinical medicine (OR, 0.74; 95% CI: 0.56-0.96).

Conclusions: The acceptability of HPV vaccines and cervical cancer screening is relatively low among medical students in southwest China. Measures should be taken to improve knowledge about cervical cancer and awareness of HPV vaccines and screening among medical students at university.

Citing Articles

The Impact of HPV Vaccination on Cervical Cancer in adolescent females: A narrative review.

Bhalerao V, Gotarkar S, Muneshwar K J Family Med Prim Care. 2024; 13(11):4775-4782.

PMID: 39722908 PMC: 11668371. DOI: 10.4103/jfmpc.jfmpc_235_24.


Cancer screening and prevention education in standardized training residents: A cross-sectional survey in single center.

Ran J, Dai Z, Wang S, Li L, Zheng Y, Qu G BMC Med Educ. 2022; 22(1):827.

PMID: 36457021 PMC: 9714006. DOI: 10.1186/s12909-022-03876-9.


Acceptability of and barriers to human papillomavirus vaccination in China: A systematic review of the Chinese and English scientific literature.

Wang D, Wu J, Du J, Ong H, Tang B, Dozier M Eur J Cancer Care (Engl). 2022; 31(3):e13566.

PMID: 35229931 PMC: 9287030. DOI: 10.1111/ecc.13566.


Prevalence of Human Papillomavirus and Genotype Distribution in Pregnant and Non-Pregnant Women in China.

Luo D, Peng M, Wei X, Pan D, Xue H, Xu Y Risk Manag Healthc Policy. 2021; 14:3147-3157.

PMID: 34349575 PMC: 8326939. DOI: 10.2147/RMHP.S288838.


Barriers and facilitators for cervical cancer screening among adolescents and young people: a systematic review.

Kirubarajan A, Leung S, Li X, Yau M, Sobel M BMC Womens Health. 2021; 21(1):122.

PMID: 33757512 PMC: 7989022. DOI: 10.1186/s12905-021-01264-x.


References
1.
Kavanagh K, Pollock K, Potts A, Love J, Cuschieri K, Cubie H . Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014; 110(11):2804-11. PMC: 4037824. DOI: 10.1038/bjc.2014.198. View

2.
Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M . Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013; 32(1):26-32. PMC: 3898718. DOI: 10.1016/j.vaccine.2013.10.085. View

3.
Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M . Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health. 2007; 7:304. PMC: 2206027. DOI: 10.1186/1471-2458-7-304. View

4.
Li R, Zhou Q, Li M, Tong S, He M, Qiu H . Evaluation of visual inspection as the primary screening method in a four-year cervical (pre-) cancer screening program in rural China. Trop Doct. 2013; 43(3):96-9. DOI: 10.1177/0049475513495615. View

5.
Jit M, Choi Y, Edmunds W . Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008; 337:a769. PMC: 2500202. DOI: 10.1136/bmj.a769. View